Related Experiment Video
Updated: Jun 17, 2025

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
Macrophage Activation Syndrome in the Setting of Rheumatic Diseases
1Department of Internal Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA. w.chatham@unlv.edu.
Abstract:
Patients with established rheumatic disorders may develop complications of macrophage activation syndrome due to severe flares of the underlying disease (adult-onset Still's disease, SLE); however, in most other rheumatic disorders, MAS develops in association with identified viral or other infectious triggers. It is therefore important to pursue appropriate studies to identify potential infectious triggers in rheumatic disease patients who develop MAS. Management is best directed toward treatment of the triggering infections and combinations of high-dose corticosteroids, calcineurin inhibitors, and biologic therapies targeting IL-1 and/or IL-6 to suppress the associated cytokine storm.
Insights
Macrophage activation syndrome (MAS) in rheumatic diseases can stem from severe flares or infections. Identifying infectious triggers is crucial for managing MAS, alongside treatments like corticosteroids and biologics targeting IL-1/IL-6.
Area of Science:
- Rheumatology
- Immunology
- Infectious Diseases
Background:
- Macrophage activation syndrome (MAS) is a severe complication in rheumatic disorders.
- MAS can arise from severe disease flares (e.g., adult-onset Still's disease, SLE) or infectious triggers.
- Identifying infectious triggers is critical for effective MAS management in rheumatic patients.
Purpose of the Study:
- To emphasize the importance of investigating infectious triggers in rheumatic disease patients presenting with MAS.
- To outline current therapeutic strategies for MAS.
Main Methods:
- Review of clinical presentations and etiologies of MAS in rheumatic diseases.
- Analysis of management approaches for MAS, including immunosuppressive and targeted biologic therapies.
Main Results:
- MAS in some rheumatic diseases (e.g., SLE, Still's disease) is linked to disease flares.
- In other rheumatic conditions, MAS is frequently associated with viral or infectious agents.
- Effective management involves treating infections and using combined therapies.
Conclusions:
- Prompt identification of infectious triggers is essential for rheumatic disease patients with MAS.
- Treatment strategies combine addressing the underlying infection with immunosuppression (corticosteroids, calcineurin inhibitors) and cytokine blockade (anti-IL-1, anti-IL-6).
- Targeting the cytokine storm is key to managing MAS and its associated rheumatic complications.
More Related Videos
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammation
The JAK-STAT Signaling Pathway

